CB-24
Non-small cell lung cancer (NSCLC) & associated pain
Pre-clinicalActive
Key Facts
Indication
Non-small cell lung cancer (NSCLC) & associated pain
Phase
Pre-clinical
Status
Active
Company
About Celtic Biotech
Celtic Biotech is a private, preclinical-stage biotech leveraging natural peptides from snake venom to develop targeted cancer therapies. The company's core platform centers on crotoxin, a neurotoxin with demonstrated selective cytotoxicity against tumor cells, initially targeting non-small cell lung cancer (NSCLC) and associated pain. As a pre-revenue entity, Celtic Biotech's near-term value drivers are the advancement of its lead program, CB-24, into clinical trials and the validation of its unique venom-derived platform. The company operates from Dublin, Ireland, and is positioned to address high-unmet-need oncology indications with a novel mechanism of action.
View full company profile